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Glioblastoma (GBM) is the most devastating and least treatable brain tumor with median
survival <15 months and extremely high recurrence rates. Promising results of immune
checkpoint blockade obtained from pre-clinical studies in mice did not translate to clinic,
and new strategies are urgently needed, particularly those targeting GBM stem cells
(GSCs) that are held responsible for drug resistance and tumor recurrence. Patient-
derived GSC cultures are critical for finding effective brain tumor therapies. Here, we
investigated the ability of the recently described monoclonal antibody Nilo1 to specifically
recognize GSCs isolated from GBM surgical samples. We employed five patient-derived
GSC cultures with different stemness marker expression and differentiation potential,
able to recapitulate original tumors when xenotransplanted in vivo. To answer whether
Nilo1 has any functional effects in patient-derived GSCs lines, we treated the cells with
Nilo1 in vitro and analyzed cell proliferation, cell cycle, apoptosis, sphere formation,
as well as the expression of stem vs. differentiation markers. All tested GSCs stained
positively for Nilo1, and the ability of Nilo1 to recognize GSCs strongly relied on
their stem-like phenotype. Our results showed that a subset of patient-derived GSCs
were sensitive to Nilo1 treatment. In three GSC lines Nilo1 triggered differentiation
accompanied by the induction of p21. Most strikingly, in one GSC line Nilo1 completely
abrogated self-renewal and led to Bax-associated apoptosis. Our data suggest that
Nilo1 targets a molecule functionally relevant for stemness maintenance and pinpoint
Nilo1 as a novel antibody-based therapeutical strategy to be used either alone or in
combination with cytotoxic drugs for GSC targeting. Further pre-clinical studies are
needed to validate the effectiveness of GSC-specific Nilo1 targeting in vivo.
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BACKGROUND
Glioblastoma (GBM, World Health Organization grade
IV glioma) is the most aggressive and least treatable
brain tumor. Current therapy for newly diagnosed GBM
includes maximal surgical resection followed by concurrent
radiation therapy with temozolomide (TMZ) and subsequent
adjuvant TMZ therapy. Despite this standard of care
treatment, median overall survival has only been extended
to 14.6 months and 5-year survival rates are less than
10% (1). In addition, there is no effective treatment at the
time of recurrence, which occurs in most of the patients.
Bevacizumab – a humanized monoclonal antibody against
VEGF (vascular endothelial growth factor) – was the
most promising therapeutic agent for recurrent GBM.
However, clinical trials have shown that, while it prolongs
progression-free survival for 3 months, this does not
translate to increased overall survival (2, 3). In fact, anti-
VEGF therapy results in increased tumor invasiveness at the
time of progression, which challenges surgical resection of
recurrent GBM (4) and possibly even worsens the quality
of life (3).
Significant progress in immuno-oncology has led to
new treatments, such as immune checkpoint blockade,
CAR (chimeric antigen receptor) T cell therapy, cytokine
therapy, oncolytic viruses and dendritic cell and peptide
vaccines. Currently, immune checkpoint blockade utilizing
monoclonal antibodies against PD-1 (programmed cell
death-1) or its ligand (PD-L1) is being extensively
studied in GBM clinical trials (e.g., NCT02336165,
NCT02617589, NCT02550249, NCT02017717); however,
their efficacy so far has been very limited. Only a small
subset of patients (8%) showed objective responses in
a trial of anti-PD-1 in recurrent GBM (5), and these
responses were transient due to acquired resistance
mechanisms (6). New candidate immunotherapeutics
are thus needed to be used in combination with
immune checkpoint blockade and overcome GBM
resistance mechanisms.
The model of cancer initiating cells proposes that tumor
growth depends on a small population of undifferentiated
cells, termed cancer stem cells (CSCs) because of their self-
renewal ability and multilineage differentiation potential (7,
8). Due to their slow cell cycle and overexpression of
efflux pumps, CSCs are held responsible for driving tumor
progression and recurrence after treatment with irradiation
and cytotoxic drugs. In fact, such treatment might lead to
Abbreviations: 7-AAD, 7-aminoactinomycin D; ANOVA, Analysis of variance;
CAR, chimeric antigen receptor; CDK2, cyclin-dependent kinase 2; CSCs,
cancer stem-like cells; DAMPs, danger-associated molecular patterns; DMEM,
Dulbecco’s Modified Eagle Medium; FBS, fetal bovine serum; GBM, glioblastoma
multiforme; GSCs, GBM stem-like cells; MRI, magnetic resonance imaging;
Nilo1, neural identification lineage from olfactory bulb 1; NSC, neural stem
cells; OPC, oligodendrocyte precursor cells; PBS, phosphate buffered saline; PD-
1, programmed death-1; PD-L1, programmed death ligand-1; RT-PCR, real time
polymerase chain reaction; SD, standard deviation; SVZ, subventricular zone;
Thy-1, thymocyte differentiation antigen 1; TMZ, temozolomide; VEGF, vascular
endothelial growth factor.
CSC enrichment after eliminating other cancer cells. Identifying
CSCs and specifically targeting signaling pathways responsible
for maintenance of their tumor-initiating and stem cell
properties are thus of high clinical relevance. Nonetheless,
specific targeting of glioblastoma stem-like cells (GSCs) is
still challenging, given that truly specific GSC markers have
not been described thus far. GSCs express markers associated
with neural stem cells (NSCs), such as CD133, Nestin,
CD44 and CD90. Substantial evidence suggests that GSCs
originate from NSCs that undergo malignant transformation
and migrate from subventricular zone (SVZ) to distant regions
of the brain (9–11). In accordance with this hypothesis,
GSCs share many features with NSCs of the SVZ, like
high proliferative and migration potential, association with
vasculature and reciprocal communication with perivascular
niche (12). Interestingly, key signaling pathways responsible for
NSC maintenance, proliferation, differentiation and migration,
like EGFR, PDGFR, p53 or PTEN, are frequently altered
in GBM. Novel therapeutic strategies directed to target
not only GSCs, but also their putative cells of origin –
NSCs of the SVZ – are thus worth considering for clinical
implementation (12).
Nilo1 (neural identification lineage from olfactory bulb) is a
monoclonal antibody generated after immunization of hamsters
with olfactory-bulb-derived mouse neurospheres (13). Nilo1
specifically marks NSCs and early progenitors in the mouse
brain (13), however, it is also able to recognize a homologous
antigen in human neurospheres derived from GBM patients (14).
Nilo1 treatment arrests mouse neurosphere proliferation (13),
suggesting that it might recognize functionally relevant molecule
involved in NSC stem cell maintenance. Nonetheless, whether
Nilo1 affects human GSC functions remained unknown.
The aim of this study was to analyze the effects of Nilo1
treatment in patient-derived GSC cultures, which represent
indispensable in vitro model for GBM basic studies and
drug development (15, 16). We previously characterized
these cells and showed that they express stem cell markers,
grow as 3D neurospheres in serum-free conditions, and
form tumors when xenotransplanted to immunodeficient mice
brain, recapitulating the phenotype and gene expression of
the original tumor (17). Our previous study revealed that
Nilo1 indeed recognizes human GSCs (14), however, in the
present work we observed that the effects of Nilo1 varied
between GSC lines derived from different patients. Namely,
one GSC line was completely resistant to Nilo1 treatment,
while four other lines were sensitive. In three of those lines,
Nilo1 led to slowing down the cell cycle and triggered
differentiation, which was accompanied by the induction of
cell cycle inhibitor p21. Most strikingly, in one GSC line
Nilo1 completely abrogated self-renewal and led to apoptosis,
associated with the induction of Bax. Overall, our data show
that Nilo1 targets a functionally relevant molecule for GSC
maintenance and suggest that patient-derived GSCs can be
stratified according to their differential Nilo1 sensitivity. This
establishes Nilo1 as a potential therapeutic agent to be used
in combination with existing immunotherapy to improve GBM
clinical outcome.
Frontiers in Oncology | www.frontiersin.org 2 August 2020 | Volume 10 | Article 1665
fonc-10-01665 August 19, 2020 Time: 11:1 # 3
Rackov et al. Nilo1 Targets Glioblastoma Stem Cells
METHODS
Isolation of GSCs, Cell Culture, and
Differentiation
Glioblastoma stem-like cells were isolated from five freshly
obtained GBM samples. All patients gave informed consent
and the use of tumor samples was approved by Hospital La
Fe (Spain) Ethics Committee. All patient-derived GSCs used
in this study have been previously characterized and have
generated tumors when xenotransplanted into nude mice [Ref.
(17), and unpublished data]. GSCs cell expansion was carried out
in serum-free DMEM/F-12 supplemented with N2, 300 ng/ml
hydrocortisone, 2 µg/ml heparin, 30 ng/ml triiodothyronine,
10 ng/ml EGF and 20 ng/ml FGF-2. GSCs were routinely
allowed to form spheres during 10 days in culture, dissociated
using Accutase and then split 1:10. Medium was replaced
every 3–5 days. For differentiation, the GSCs were allowed
to form spheres during 6 days and then the medium was
replaced with differentiation medium, containing the same
basal media supplemented with 10% FBS and lacking EGF
and FGF-2. All experiments were performed in mycoplasma-
free conditions.
Mesenchymal Stem Cell Culture
Human adipose tissue samples were obtained at private plastic
surgery clinic (Clinica Dra. Isabel Moreno) from lipoaspiration
procedures from 8 healthy patients under surgery by aesthetic
reasons, aged between 18 and 35, following written informed
consent and ethical research project approval by both Clinica
Dra Isabel Moreno and Hospital General Foundation in
Valencia ethical boards under the research project of Dr.
Escobedo-Lucea. All the patients were previously screened
for human immunodeficiency virus (HIV), hepatitis C and
other infectious diseases. Cells were obtained following the
protocol established from Planat-Benard (18), with a few
modifications. Briefly, samples were digested in a solution of
1 mg/ml collagenase type I from Clostridium Histolyticum
(Gibco, Grand Island, NY, United States) for 90 min at
37◦C. The cells were then washed with 0.5% of HSA in
Hank’s balanced salt solution (Gibco, Grand Island, NY,
United States) and after discarding mature adipocytes, seeded
in culture flasks with growth medium, Dulbecco’s modified
Eagle’s medium (Invitrogen) supplemented with human or
bovine serum mesenchymal stem cell qualified (Gibco, Grand
Island, NY, United States), in a humidified atmosphere of
95% air and 5% CO2 at 37◦C. The medium was replaced
every 3 days. When primary culture became subconfluent,
cells were detached using Tryple (Invitrogen) and subcultured
in growth medium.
Fluorescence Confocal Microscopy
Glioblastoma stem-like cell tumorspheres or dissociated single
cells were plated on Matrigel-coated coverslips, fixed in 4%
paraformaldehyde for 10 min and blocked with 10% BSA/0.05%
Tween for 1 h at room temperature. Primary Nilo1 monoclonal
antibody was generated by the fusion of hamster B cells
and the mouse myeloma X63Ag8 (13) and purified in CNB-
CSIC (Madrid, Spain). Cells were incubated with Nilo1 1:100
overnight at 4◦C, followed by 1:200 FITC-conjugated anti-
hamster secondary antibody from BD. F-actin was stained with
Phalloidin-iFluor 647 (1:40, 1 h at room temperature, Abcam)
and nuclei with DAPI (1:5000, 10 min at room temperature,
Sigma). For stem-like and differentiation markers we used anti-
GFAP (1:500, Dako) and anti-OLIG2 (1:500, Millipore), followed
by Alexa fluor 555 goat anti-rabbit antibody (1:1000) from
Invitrogen. To estimate cell viability within the tumorspheres,
5 µg/ml 7-AAD (BioLegend) was used. Coverslips were mounted
with Fluorsave (Calbiochem). The images were taken using
the glycerol ACS APO 20x NA0.60 immersion objective of a
confocal fluorescence microscope (SPE, Leica-Microsystems) and
analyzed using FIJI software.
Nilo1 Treatment and Cell Viability Assay
Glioblastoma stem-like cell tumorspheres or dissociated single
cells were plated in 96-well plate at a density of 3000 cells per
well and treated with Nilo1 monoclonal antibody or InVivoMAb
hamster anti-mouse CD3ε (BioXCell) as irrelevant control, at
a concentration of 0.5 mg/ml for indicated time points. For
7-day treatment, the media was replenished once on Day 3.
Cell viability was assessed using CellTiter 96 AQueous One
Solution Cell Proliferation Assay from Promega, according to
manufacturer’s instructions.
Neurosphere Formation Assay
After tumorsphere dissociation, GSCs were plated in 96-well
plate at a density of 50 cells per well and treated as above,
with 6 replicates per condition. Neurospheres were counted and
photographed after 21 days.
RNA Extraction and RT-PCR Analysis
Total RNA was extracted with TRIzol (Sigma) according to the
manufacturer’s instructions and 1 µg RNA was retro-transcribed
using cDNA kit from Applied Biosciences. Real-time PCR was
performed using TB Green Premix Ex Taq RR420 (Takara) and
detected by ABI PRISM 7900HT (Applied Biosystems). Data
were analyzed using SDS 2.4 software (Applied Biosystems),
normalized to the expression of β-actin and represented as
the fold-change with respect to controls. All primers were
synthesized, desalted and purified by Sigma, and the sequences
were as follows: NES, 5′-GAGGTGGCCACGTACAGG-3′
(forward) and 5′-AAGCTGAGGGAAGTCTTGGA-3′ (reverse);
PROM1, 5′-GGAAACTAAGAAGTATGGGAGAACA-3′ (for-
ward) and 5′-CGATGCCACTTTCTCACTGAT-3′ (reverse);
OLIG2, 5′-AGCTCCTCAAATCGCATCC-3′ (forward) and
5′-ATAGTCGTCGCAGCTTTCG-3′ (reverse); PDGFRA, 5′-CC
ACCTGAGTGAGATTGTGG-3′ (forward) and 5′-TCTTCAGG
AAGTCCAGGTGAA-3′ (reverse); S100B, 5′-GGAAGGGGTG
AGACAAGGA-3′ (forward) and 5′-GGTGGAAAACGTCGAT
GAG-3′ (reverse); GFAP, 5′-GTGGTGAAGACCGTGGAGAT-3′
(forward) and 5′-GTCCTGCCTCACATCACATC-3′ (reverse);
MAP-2, 5′-CCTGTGTTAAGCGGAAAACC-3′ (forward) and
5′-AGAGACTTTGTCCTTTGCCTGT-3′ (reverse).
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Flow Cytometry
Glioblastoma stem-like cell tumorspheres were dissociated using
Accutase (5 min, 37◦C) and cells were stained with anti-
PDGFRA-PE (BD), -CD133-APC (Miltenyi Biotec), -CD24-FITC
(BD) and -CD90-FITC (Beckman Coulter) at the dilution of
1:100. The cells were analyzed on Attune Acoustic Focusing
Cytometer from Applied Biosystems. The data were analyzed
using FlowJo software (Tristar).
Apoptosis Analysis
Following Nilo1- or irrelevant control-treatment, the
tumorspheres were dissociated with Accutase (5 min, 37◦C),
stained with Pacific Blue Annexin V Apoptosis detection kit
(BioLegend) according to the manufacturer’s protocol, and
analyzed by flow cytometry.
Cell Cycle Analysis
To analyze cell cycle, dissociated tumorspheres were washed with
PBS, permeabilized with detergent, stained with PI for 30 min
at 37◦C according to the manufacturer’s instructions (DNA-Prep
Reagent Kit, Beckman Coulter) and analyzed by flow cytometry.
Statistical Analysis
Statistical significance was determined by unpaired two-tailed
Student’s t-test for comparisons between two groups, or by
1- or 2-way ANOVA for multiple comparisons, followed by
Bonferroni post hoc test. Differences were considered significant
when p < 0.05. All statistical analyses were conducted using
Prism 8 software (GraphPad).
RESULTS
Human GBM Neurospheres Stain
Positively for Nilo1
Nilo1 has been shown to recognize NSCs in mice, as well as
human GBM cells derived from patients. While Nilo1 arrests
proliferation in mouse NSCs, whether Nilo1 has such an effect
on human GSCs remained unknown. In this study, we used
GSC-enriched cultures isolated from five GBM patients (GBM18,
GBM27, GBM38, GBM123, and GBM128B) and grew them
as neurospheres in growth-factor-enriched stem cell medium
(19). Nilo1 gave positive staining in all five tested lines
(Figure 1A, left panels), confirming our previous findings that
Nilo1 recognizes human GBM neurospheres (14). To visualize
cell morphology, neurospheres were dissociated into single cells
and F-actin (filamentous actin) was stained with phalloidin.
Although the relative abundance of Nilo1-positive cells varied
between different GSC lines, only a small proportion of cells were
positive for Nilo1 within each line (Figure 1A, right panels).
Nilo1 Treatment Reduces Cell Viability
and Self-Renewal Properties in a Subset
of GSCs
To investigate the effect of Nilo1 stimulation on patient-
derived GSCs, we allowed neurospheres to form during
10 days in stem cell culture, and then treated them for
7 days with 0.5 mg/ml Nilo1, the highest concentration that
efficiently inhibited proliferation in mouse neurospheres
(13). The numbers of viable cells were similar in Nilo1- and
irrelevant antibody control-treated cells, except in GBM38,
where Nilo1 treatment slightly reduced the numbers of
viable cells compared with control (Figure 1B). Cell cycle
analysis showed that during neurosphere formation G1
phase lengthens overtime and that the division cycles
become longer resulting in decreased proportions of
actively proliferating cells at Day 10 compared with Day
3 of cell culture (Supplementary Figure S1). We thus
hypothesized that Nilo1 treatment might have an effect on
the growth of single cells during neurosphere formation.
To investigate this, we dissociated the neurospheres and
treated them with Nilo1 or an irrelevant control antibody
for 3 or 7 days. As before, Nilo1 didn’t show any effect
on the viability of GBM18 and GBM123 cells compared
with control (Figure 1C). However, in this setting Nilo1
treatment significantly reduced viable cell numbers in GBM27
and GBM128B cells (Figure 1C). Most strikingly, Nilo1
completely abrogated cell growth in GBM38 (Figure 1C). To
exclude the possibility that Nilo1 treatment would be toxic to
normal stem cells, we performed a 7-day-Nilo1 treatment on
adipose tissue-derived mesenchymal stem cells. Our results
confirmed that the viability of normal stem cells was not
altered, suggesting that Nilo1 effects are restricted to GSCs
(Supplementary Figure S2).
Since Nilo1 treatment affected the viability of replicating
single cells and not the fully formed spheres, we considered
that Nilo1 might interfere with GSC self-renewal properties.
We thus performed sphere-formation assay over the course
of 3 weeks to investigate whether Nilo1 treatment would
affect the ability of GSCs to form neurospheres. As in viability
assay, Nilo1 didn’t show any effect on sphere formation in
GBM18 and GBM123 cells compared with control treatment
(Figure 2 and Supplementary Figure S3). However, Nilo1
effectively reduced GSC stemness in GBM27, GBM38 and
GBM128B, as indicated by decreased number of spheres
at 21 days after plating (Figure 2 and Supplementary
Figure S3). Increased proportions of adherent cells were
observed in Nilo1-treated GBM18 and GBM128B (Figure 2
and Supplementary Figure S3), suggesting that Nilo1
might interfere with sphere formation by inducing cell
differentiation. Again, most striking effect was detected in
GBM38, where not a single sphere could be observed after
the Nilo1 treatment (Figure 2). To discard the possibility
that some GSC lines were particularly sensitive to Nilo1
treatment due to suboptimal growing conditions and/or cell
death, we performed 7-AAD staining of GBM27, GBM38,
and GBM128B control neurospheres to check for the
presence of non-viable cells at the outermost neurosphere
layers as a sign of non-optimal growth (20). Nonetheless,
we didn’t detect a significant number of 7-AAD-positive
cells in external layers of these neurospheres, suggesting
they were healthy and viable (Supplementary Figure S4).
Collectively, our data showed that Nilo1 stimulation
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FIGURE 1 | Nilo1 treatment reduces the viability of GSCs. (A) Confocal microscopy showing Nilo1-positive staining in five lines of patient-derived GSCs grown as
neurospheres (left) or after dissociation to single cells (right). DAPI is shown in blue. Scale bar shows 100 µm. (B) MTS assay showing the effect of Nilo1 (0.5 mg/ml)
7-day-treatment on GSC tumorsphere viability compared with the i.c. (irrelevant control, hamster anti-mouse CD3ε). Data were normalized to i.c. treatment and
show mean ± SD (n = 3), *p < 0.05, Student’s t-test. (C) GSCs were dissociated to single cells and treated with Nilo1 or i.c. (0.5 mg/ml) for 3 or 7 days. MTS assay
showed a reduction in GSC viability after Nilo1 treatment. Data were normalized to day 0 and show mean ± SD (n = 3), *p < 0.05, **p < 0.01, ****p < 0.0001,
two-way ANOVA (with Bonferroni correction).
significantly reduces stemness in three out of five tested
patient-derived GSC lines.
Differentiation Reduces the Ability of
Nilo1 to Recognize GSCs
Our data showed that Nilo1 affects GSC self-renewal properties,
which suggested that Nilo1 specifically targets cells in stem-like
state. To investigate this, we next asked whether Nilo1 capacity
to recognize GSCs would decrease upon their differentiation.
Like NSCs, GSCs have the ability to differentiate into three
downstream cell lineages: neuron, astrocyte and oligodendrocyte
(9). However, differentiation efficiency and lineage choice vary
significantly between each GSC line (15). To induce GSC
differentiation, we first allowed tumorspheres to form during
6 days in presence of EGF and FGF-2, and then removed
growth factors from culture medium and added 10% FBS. We
noted that GSCs did not undergo cell death upon growth factor
withdrawal, but instead tumorspheres attached to the plate and
the cells started to migrate away from the sphere and change
their morphology. To assess the efficacy of GSC differentiation,
we analyzed stem vs. differentiation markers both at the levels of
mRNA and protein expression after 4 days of differentiation. Of
note, similar results were obtained using a 10-day differentiation
protocol (data not shown). Following differentiation, GBM18
significantly downregulated NES (Nestin), a cytoskeletal protein
typically expressed by NSCs and progenitor cells in developing
brain (21), and PROM1 (Prominin1, i.e., CD133), a cell
Frontiers in Oncology | www.frontiersin.org 5 August 2020 | Volume 10 | Article 1665
fonc-10-01665 August 19, 2020 Time: 11:1 # 6
Rackov et al. Nilo1 Targets Glioblastoma Stem Cells
FIGURE 2 | Nilo1 treatment reduces GSC self-renewal properties. For sphere-formation assay, GSC neurospheres were dissociated and 50 cells were plated per
well in a 96-well plate. GSCs were treated with Nilo1 or irrelevant control (i.c.) at 0.5 mg/ml and spheres were counted after 3 weeks. Scale bar shows 100µm. Data
show mean ± SD (n = 6), *p < 0.05, ***p < 0.001, ****p < 0.0001, Student’s t-test. NS, not significant.
surface marker of NCSs (22) (Figure 3A). In addition,
we detected decreased expression of oligodendrocyte lineage
markers (OLIG2 and PDGFRA) in differentiated GBM18 cells,
which was confirmed by flow cytometry (Figure 3A) and
immunofluorescence analysis (Figure 3B). Compared with their
stem-like counterparts, differentiated GBM18 cells showed an
increase in CD24 levels, which has been correlated with neuronal
differentiation and neuronal maturation (23) (Figure 3A). In
GBM27 line, differentiation induced significant decrease of NES
and OLIG2 expression, paralleled by an increase in astrocyte
markers S100B and GFAP (Figure 3C). Increased levels of GFAP
after differentiation were confirmed by immunofluorescence
analysis (Figure 3D), showing that GBM27 adopted an astrocyte
phenotype. In addition, flow cytometry analysis revealed that
differentiated GBM27 cells upregulated CD24 (Figure 3E),
which can be found in neurons undergoing differentiation as
well as astrocytes (24). In GBM38, differentiation induced an
increase in CD24 levels, suggesting their neuronal differentiation
(Figure 3F). Stem-like GBM38 cells showed relatively high
levels of GFAP which was decreased after differentiation
(Figure 3G). Conversely, the levels of OLIG2 increased,
suggesting the presence of oligodendrocyte differentiation in
GBM38 (Figure 3G). As evidenced by increased GFAP levels and
decrease in NES and OLIG2 expression, GBM123 differentiated
into astrocytes (Figures 3H,I). Finally, GBM128B line evidently
differentiated into neurons, as we detected decreased levels of
PDGFRA and OLIG2 together with increased expression of CD24
and MAP2 (Figures 3J–L).
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FIGURE 3 | Stemness and differentiation markers in stem-like and differentiated GSCs. GSCs were grown in FBS-free media supplemented with growth factors for
10 days (stem-like cells). To induce differentiation, GSCs were grown in the same media for 6 days to form tumorspheres and then changed to growth-factor-free
media supplemented with 10% FBS for additional 4 days (differentiated cells). (A) RT-PCR and flow cytometry analyses of mRNA and surface protein expression for
GBM18. (B) Immunofluorescence analysis showing OLIG2 levels in GBM18. (C) RT-PCR analysis and (D) immunofluorescence showing the induction of astrocyte
markers in GBM27. Flow cytometry showing increased CD24 surface levels in GBM27 (E) and GBM38 (F) after differentiation. (G) Immunofluorescence showing a
decrease in GFAP and an increase in OLIG2 levels in GBM38 after differentiation. (H) Immunofluorescence analysis of GBM123, showing an increase in GFAP and
decrease in OLIG2 levels after differentiation. (I) RT-PCR showing increased GFAP expression in GBM123. (J) RT-PCR and (K) flow cytometry showing decreased
PDGFRA and increased neuronal markers MAP2 and CD24 in GBM128B following differentiation. (L) Immunofluorescence showing a decrease in OLIG2 levels in
differentiated GBM128B cells. Gene expression analysis was done for all GSC lines at once and the data were normalized to GBM38, so the relative fold change can
be appreciated between different GSC lines. Data show mean ± SD (n = 3), **p < 0.01, ***p < 0.001, ****p < 0.0001, Student’s t-test. For flow cytometry, negative
staining control is in gray. Shown are representative histogram plots of two experiments performed. For immunofluorescence, white bar shows 50 µm. Shown are
representative images of two independent experiments performed.
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FIGURE 4 | Nilo1 recognizes GSCs in stem-like state. GSCs were grown as in Figure 3. Confocal microscopy showing reduced proportions of Nilo-1 positive cells
in differentiated GBM123, GBM27, GBM128B and GBM38 cells (right) compared with their stem-like equivalents (left). Scale bar shows 100 µm.
We next analyzed the ability of Nilo1 to recognize GSCs
cultured in stem cell conditions vs. those cultured in
differentiation medium. Confocal microscopy (Figure 4)
showed that, compared with tumorspheres grown in stem cell
medium (left panels), the proportions of Nilo1-positive cells
dramatically decreased along with the loss of stem cells upon
GSC differentiation (right panels). Overall, these data showed
that the decrease of Nilo1 ability to recognize GSCs correlates
with the degree of their differentiation, which is in line with the
hypothesis that Nilo1 identifies stem-like GSCs.
Nilo1 Induces Apoptosis in GBM38
The effect of Nilo1 treatment was the most evident in GBM38
cells, since it sharply reduced cell viability and completely
abrogated sphere formation in these cells (Figures 1C, 2). To
get an insight of the mechanism by which Nilo1 kills GBM38
cells, we tested the ability of Nilo1 to induce apoptosis. After
7 days of Nilo1 treatment, flow cytometry analysis revealed
significantly increased AnnexinV+/7-AAD+ dead cell percentage
(33 vs. 47%) in Nilo1-treated cells compared with controls
(Figure 5A, upper panels). In addition, the percentage of
apoptotic AnnexinV+/7-AAD− cells was increased (4 vs. 13%),
which suggested that Nilo1 acts through induction of apoptosis.
To verify this, we assessed the ratio between apoptosis promoter
BAX and apoptosis inhibitor BCL2 expression, which is known to
determine the cell’s susceptibility to die in response to apoptotic
stimulus (25). Indeed, BCL2 tended to decrease already at 3 days
after Nilo1 treatment, and it was significantly decreased at 7 days,
while the expression levels of BAX were significantly increased
at this time point in Nilo1-treated cells compared with controls
(Figure 5A, lower panels). These results demonstrated that Nilo1
inhibits GBM38 growth by inducing apoptosis.
Nilo1 Arrests Cell Cycle in GBM18,
GBM27, and GBM128B
We also tested the capacity of Nilo1 to induce cell death in
other GSCs, however flow cytometry showed similar proportions
of apoptotic and dead cells in GBM18, GBM27, GBM123 and
GBM128B after 3 (data not shown) and 7 days of Nilo1
compared with control treatment (Figure 5B). As shown in
Figure 1C, Nilo1 treatment reduced the numbers of viable cells
in GBM27 and GBM128B, although these cells continued to grow
during the course of the experiment. This finding indicated that
Nilo1 might affect cell cycle progression in these cells, without
having a pro-apoptotic effect. We therefore analyzed cell cycle
profiles in GSCs, and found that Nilo1 treatment increased the
percentage of cells in G0/G1 phase (69.7 vs. 74.6% in GBM27
and 63.0 vs. 69.2% in GBM128B, Figure 5C) compared to
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FIGURE 5 | Nilo1 induces apoptosis and cell cycle arrest in GSCs. Neurospheres were dissociated and treated with Nilo1 (0.5 mg/ml) or with hamster anti-mouse
CD3ε) as an irrelevant control (i.c.) for 7 days. (A) Flow cytometry analysis shows increased proportions of apoptotic (Annexin V+) cells and dead (PI+/Annexin V+)
cells in GBM38 after Nilo1 treatment (upper panel). RT-PCR analysis shows increased BAX and decreased BCL2 expression in GBM38, indicative of apoptosis
(lower panel). (B) Flow cytometry analysis showing no significant change in apoptotic (Annexin V+) cells and dead (PI+/Annexin V+) cells in GBM18, GBM27,
GBM123 and GBM128B after Nilo1 treatment. (C) Cell cycle analysis shows decreased proportions of proliferating (G2/M) and increased proportions of G1-arrested
(G1/G0) GBM27 and GBM128B cells after Nilo1 treatment. (D) Nilo1 treatment reduces the expression of stemness marker PROM1 in GBM18 and induces the
expression of astrocyte marker GFAP in GBM27. The expression of P21 is significantly induced in GBM18, GBM128B and GBM27 after 7-day Nilo1 treatment.
(E) Flow cytometry analysis showing and increase of CD24, a neuronal differentiation marker, in GBM18, GBM27 and GBM128B after Nilo1 treatment. Panels
(A–C,E) shown are representative histograms or dot plots of two experiments performed. Panels (A) and (D) data were normalized to GBM38 day 3 i.c. and show
mean ± SD (n = 3), *p < 0.05, ****p < 0.0001, 1- or 2-way ANOVA (with Bonferroni correction).
controls. In line with this, the proportions of proliferating cells
in G2/M phase were reduced (24.5 vs. 16.3% in GBM27 and
28.0 vs. 24.5% in GBM128B, Figure 5C), suggesting that in
presence of Nilo1 cells continue growing but at lower speed.
This phenomenon of slowing down the cell cycle is known
to occur during differentiation (26) and has been associated
with neurogenic differentiation of neural stem-like progenitor
cells during brain development (27). Therefore, these results,
together with the fact that adherent cells were observed in
Nilo1-treated GBM18 and GBM128B cells (Figure 2), led us
to hypothesize that Nilo1 treatment might be inducing GSC
differentiation. We thus examined the expression of stemness
and differentiation markers, and found that Nilo1 treatment
led to a reduction of Prominin1 (CD133) in GBM18, and
induction of GFAP in GBM27 (Figure 5D). The induction of
astrocyte-specific gene expression in GBM27 clearly pointed to
a differentiation-inducing effect of Nilo1. Furthermore, RT-PCR
analysis revealed that Nilo1 significantly induced the expression
of p21 – a cyclin-dependent kinase 2 (CDK2) inhibitor – in
GBM18, GBM27 and GBM128B (Figure 5D). Overexpression
of cell cycle inhibitors is a key event ultimately leading to cell
cycle arrest and induction of cell type-specific gene expression
in cancer cells (28). In support of this, flow cytometry analysis
showed that Nilo1 treatment significantly induced the expression
of CD24, a marker of neuronal differentiation, in GBM18,
GBM27, and GBM128B. Collectively, our findings thus point
to a p21-dependent mechanism by which Nilo1 acts to reduce
proliferation and induce differentiation in GSCs.
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DISCUSSION
Nilo1 monoclonal antibody was generated against mouse
neurospheres and it specifically recognizes NSCs in the mouse
brain (13, 14). This antibody can be coupled with magnetic
nanoparticles to identify mouse NSCs in their niche in vivo, and
track their migration by MRI (magnetic resonance imaging) in
response to brain damage (14). In vitro, Nilo1 treatment arrests
mouse neurosphere proliferation, which suggested that Nilo1
targets a molecule functionally relevant for stem cell maintenance
(13). In addition to mouse NSCs, Nilo1 was previously shown
to recognize a homologous antigen within GBM patient-derived
neurospheres (14). This raised the possibility that Nilo1 might
be the first therapeutic drug targeting GSCs (29); however this
remained to be investigated. In this work, we establish that, (1)
Nilo1-specific targeting of GBM neurospheres depends on their
stem-like phenotype, (2) Nilo1 affects the viability of GSCs but
not normal stem cells, (3) in a portion of patient-derived GSCs
Nilo1 treatment affects cell cycling and triggers differentiation
in parallel with p21 induction, and (4) Nilo1 treatment kills
a subset of patient-derived GSCs through a Bax-associated
apoptotic mechanism.
Glioblastoma is characterized by extreme inter- and intra-
tumoral heterogeneity, resulting in substantial differences
in clinical characteristics and response to treatment. This
heterogeneity is also reflected in GSC populations, showing
different molecular and functional phenotypes that could explain
why the effects of Nilo1 treatment varied between different GSC
lines. For their growth and stemness maintenance, GSCs rely
on a very complex network of signaling pathways, including
Notch, Hedgehog and Wnt. Whether due to chromosomal
instability, or different signaling events, yet our GSCs showed a
remarkable difference in the expression of Notch, Hedgehog and
Wnt downstream effectors (Supplementary Figure S5), which
regulate key events in cell fate determination and proliferation.
As there is considerable redundancy among these pathways, some
GSCs lines might bypass the effects of Nilo1 and continue to grow
despite blocking one route.
It would certainly be of relevance to find a marker
defining Nilo1-sensitive GSC subtype. Currently, there is no
universal marker for isolating GSCs or distinguishing them
from NSCs. Our data showed that only GBM18 expressed
CD133 (Prominin1), confirming that CD133 is not a universal
marker for GSCs (30). GBM18, GBM27, and GBM123 expressed
Nestin, while GBM128B showed the expression of PDGFRA and
OLIG2. GBM38 lacked all putative stem cell markers except
for GFAP, which is highly expressed in astrocytoma (31). Yet,
GBM38 exhibits the most aggressive tumor growth in vivo
(32) and was shown to be more resistant than other lines to
a panel of drugs currently used in clinical practice (17). The
fact that Nilo1 most effectively killed GBM38 cells therefore
has twofold implications. First, our findings suggest that Nilo1
might be used in combination with current drugs to kill the
most resistant GSCs. Second, in combination with therapeutic
strategies that specifically target GSCS by their markers – such
as CART (chimeric antigen receptor T cell) therapy – Nilo1
might aid to eliminate GSCs that lack most of the widespread
CSC markers. We consider these possibilities worth investigating
in future studies.
Glioblastoma stem-like cells, like normal stem cells, are
resistant to conventional therapy that affects more differentiated
cells of the bulk tumor. Therapies designed to specifically kill
CSCs or target the pathways that maintain their stem-cell state
and induce differentiation, might thus prove useful in the clinic.
Because CSCs express specific markers, antibody-based therapies
are considered as an effective approach to induce CSC cell death
either directly, or to be used as antibody-drug conjugates. Indeed,
anti-CD44 antibody can induce differentiation and apoptosis
in leukemia and bladder cancer cells (33, 34), while CD133+
cancer cells can be targeted using an anti-CD133 antibody
conjugated with cytotoxic drug (35). Nonetheless, there are
currently no specific markers that tell apart CSCs from NSCs,
and on-target/off-tumor toxicity represents one of the major
challenges of CSC-targeted therapy. Nilo1 was first described
as a monoclonal antibody that labels mouse NSCs (13), which
raised the possibility that Nilo1 might also recognize NSCs in
humans. This will certainly need to be explored in preclinical
studies; nonetheless, our results showed that Nilo1 treatment
did not have any toxic effects on normal human mesenchymal
stem cells. To avoid its interaction with NSCs, using Nilo1
conjugated with gold nanoparticles was proposed for location-
restricted photo-ablation therapy. In that case, any Nilo1+NSCs
would be protected by their location (in SVZ), which is distinct
from the location of the tumor (36). Alternatively, recent studies
revealed that glioblastomas may originate from NSCs of the SVZ
that undergo malignant transformation and give rise to GSCs
(12). Having this in mind, therapeutic strategies directed toward
common molecular targets in NSCs and GSCs might be critical
for achieving better prognosis for GBM patients.
An important factor for developing antibody-based therapies
is the presence of blood–brain barrier (BBB). Intact BBB
efficiently prevents crossing of systemically administered drugs
and monoclonal antibodies larger than 400 Da from the
bloodstream into the brain parenchyma (37). GBM is often
characterized by a disruption of BBB and open endothelial tight
junctions, which allow limited amounts of drugs to reach the
tumor site. Nonetheless, the extent of BBB disruption is difficult
to determine and varies from patient to patient. To bypass BBB,
locoregional delivery using intracerebral placement of catheters
can be used as a strategy for enhancing intraparenchymal drug
delivery (37). Pharmacodynamics and pharmacokinetics studies
will need to be performed to determine the in vivo efficacy
of Nilo1 antibody.
Our results establish Nilo1 as a potential therapeutic drug
targeting GSCs, with several possible applications. First, our data
show that Nilo1 labels GSCs, hence conjugating Nilo1 with a dye
might allow for better visualization of highly infiltrative GBM
tumors. Second, Nilo1 treatment directly induced cell death in
one patient-derived GSC line. In addition, the fact that Nilo1
treatment disabled sphere formation and triggered differentiation
in a subset of patient-derived GSCs, suggested that these cells,
by losing self-renewal and stemness properties, might become
susceptible to standard chemotherapy and radiotherapy. Finally,
the fact that all tested GSC lines were Nilo1-positive raises the
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possibility that conjugating Nilo1 with a cytotoxic drug might
encompass the full spectrum of GSC molecular subtypes. We
believe that future studies exploring this wide range of possible
applications might set the stage for Nilo1 humanized antibody
development and clinical trials.
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FIGURE S1 | Cell cycle analysis for GBM38 line at different time points during
neurosphere formation.
FIGURE S2 | MTS assay showing that Nilo1 treatment does not affect the viability
of mesenchymal stem cells. Data were normalized to day 0 and show
mean ± SD (n = 3).
FIGURE S3 | Sphere formation assay at day 14, showing that Nilo1 treatment
impedes sphere formation in GBM18, GBM128B, and GBM38. Scale bar shows
100 µm.
FIGURE S4 | Immunofluorescence analysis of GBM27, GBM38 and GBM128B
tumorspheres showing the proportions of non-viable cells stained with 7-AAD.
Scale bar shows 50 µm.
FIGURE S5 | RT-PCR showing different expression levels of Hedgehog (GLI1),
Notch (HEY2), and Wnt (BMP4) downstream effectors in GSC lines.
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